Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

INTRODUCTION: CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106 first-in-human study demonstrated a favorable safety profile and promising antibody response. We investigated long-term safety, tolerability and antibody re...

Descripción completa

Detalles Bibliográficos
Autores principales: Farlow, Martin R, Andreasen, Niels, Riviere, Marie-Emmanuelle, Vostiar, Igor, Vitaliti, Alessandra, Sovago, Judit, Caputo, Angelika, Winblad, Bengt, Graf, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410460/
https://www.ncbi.nlm.nih.gov/pubmed/25918556
http://dx.doi.org/10.1186/s13195-015-0108-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410460/
https://www.ncbi.nlm.nih.gov/pubmed/25918556
http://dx.doi.org/10.1186/s13195-015-0108-3

Ejemplares similares